It is well established that ageing is associated with the functional decline of endocrine organs and therefore a risk factor for metabolic conditions, such as type 2 diabetes, in later life. Little work has been done to define the effects of ageing on the transcriptome of the endocrine pancreas and how epigenetic mechanisms could contribute to these effects. In this study we analysed the dynamics of gene transcription during ageing of the endocrine pancreas and measured promoter DNA methylation at a selected number of loci with age-associated transcriptional changes. We found age-related molecular signatures of ‘inflammageing’ and ‘type 2 diabetes’, with parallel changes in DNA methylation of genes contributing to this effect. We propose that these (epi)genetically regulated ‘signature’ genes represent novel mediators of the age-associated decline in islet-cell function.
We identified 3.7% genes within the islet transcriptome that were differentially expressed between young and old islets, by 1.5-fold or more, with the majority (84.3%) showing increases in expression with age. Pathway analysis revealed an enrichment of upregulated genes implicated in inflammation and immune responses (e.g. genes encoding homeostatic and inflammatory chemokines, interferon and interleukin, complement genes and genes encoding MHC molecules, which are involved in antigen presentation), suggestive of age-associated increases in endocrine pancreas inflammation (or inflammageing). Inflammageing, a term used to describe an imbalance between inflammatory and anti-inflammatory networks that causes lifelong antigenic burden and exposure to damaging agents, is thought to be a major driving force for frailty and common age-related pathologies [26]. Our findings lead us to propose that inflammageing may contribute to the known age-associated decline in beta cell function and consequential increase in type 2 diabetes risk. There is a substantial lack of functional studies that link those processes to endocrine function. Importantly, a transgenic mouse with increased expression of Ccl2 (encoding chemokine [C-C motif] ligand 2) in their beta cells developed diabetes [27]; this is consistent with our observed age-related upregulation of Ccl2 being detrimental for endocrine pancreatic function. Our findings are also consistent with studies showing that cells undergoing senescence start secreting a large number of pro-inflammatory cytokines and chemokines, as part of the so-called ‘senescence-associated secretory phenotype’ (SASP) [28]. We identified several genes that encode SASP proteins and that were upregulated with age in rat islets, including Igfbp6, Mmp12, Mmp14, Timp2 and Fn1.
Many other genes that exhibited transcriptional dysregulation with age have been linked previously with type 2 diabetes (ESM Table 1). For example, microarray studies performed on human pancreatic islets isolated from patients with type 2 diabetes and glucose-tolerant controls identified, among other changes, overexpression of ENPP1, TSPAN4, TSPAN8, CSRP1, REG3A and REG3G [29, 30], genes that were also upregulated with age in our study. Some of the genes identified as being differentially expressed with age have been previously implicated in type 2 diabetes through GWAS [31]. These include TSPAN8, KCNQ1 and ITGB6 loci (upregulated with age in rat islets) and some of these polymorphisms have been predicted to affect beta cell function. Other genes expressed differentially with age have been previously implicated in endocrine pancreas function (ESM Table 1). These genes could therefore represent novel mediators of the age-associated decline in islet cell function.
As expected from the nature of this study, we found a number of gene expression ‘signatures’ of the ageing process. Fifteen of the genes upregulated with age (C1qa, C1qb, Ctss, S100a6, Lgals3, Mgst1, S100a4, Fcgr2a, Gbp2, Il33, Litaf, Serping1, Spp1, Laptm5 and Txnip) had similar age-related gene expression changes to the ones reported in a recent meta-analysis of mouse, rat and human tissues (over ten tissues but not including pancreatic islets) [32, 33]. These genes therefore appear to be part of a common signature of ageing across tissues that include a total of 73 genes [32, 33].
Age-related changes in DNA methylation in the endocrine pancreas have not been reported prior to this study. We focused our analysis on a restricted number of loci (n = 46), based on the microarray differential expression analysis, with the aim of establishing correlations between DNA promoter methylation and transcriptional activity. Globally, 19 of the 46 loci analysed (41%) showed absolute differences in methylation of between 5% and 28%. Fourteen of the 19 differentially methylated genes (74%) demonstrated a direction of change consistent with differences in expression, suggesting that DNA methylation may contribute to the transcriptional changes. Notably, 13 of these 14 loci reflected hypomethylation with age and were associated with increased expression. These changes were observed at loci related to ‘inflammageing’ and endocrine function. Global analysis of DNA methylation, as measured by methylation levels of LINE-1 repeats, further suggested that hypomethylation might be an epigenetic hallmark of ageing in rat islets. Importantly, a major preponderance for loss of DNA methylation has been observed recently in pancreatic islets of type 2 diabetes patients [9, 10].
Our current study has one important limitation, which is the use of islet cells instead of purified cell types. A clear advantage of using islet cells is that this reflects the physiology of the endocrine pancreas and takes into account the milieu of insulin-secreting cells. However, the transcriptomic and epigenetic data analyses are made more complex given potential confounding effects brought about by morphology and cell-type composition changes with age. In this study, we found clear evidence for cellular senescence, collagen deposition and macrophage infiltration in a significant proportion of aged islets (affecting ~20%, ~ 42% and ~27% of all islets, respectively). Associated with these morphological changes, 11 collagen genes were upregulated in our dataset (ESM Table 4) as was the macrophage marker CD68 (Fig. 4c). Importantly, age-related morphological changes in the pancreatic islets, such as beta cell hyperplasia and intra-insular fibrosis with accumulation of macrophages, have been recognised to occur spontaneously in aged (predominantly male) rats fed ad libitum [14, 15]. Similar morphological changes have also been reported in several rat models of diabetes and in obese rat strains [34–36]. Pancreatic islet pathology is highly variable in patients with type 2 diabetes, with moderate changes in beta cells, islet fibrosis and amyloidosis being commonly reported [14]. These morphological changes are likely to have an impact on DNA methylation patterns. Whether the altered DNA methylation seen in this current study reflects cell-type composition differences or relates to transcriptional activity only, or a combination of both, is difficult to ascertain. Our studies using a demethylating agent in an insulin-secreting cell line suggest that loss of DNA methylation might be responsible, at least in part, for the observed transcriptional changes at five loci (Fbp2, S100a4, Lgals1, Tf and Cxcl9). Cxcl9 is of particular interest as it is upregulated at both the mRNA (ranking as second highest gene upregulated with age in our dataset; ESM Table 4) and protein level (Fig. 3b) and is hypomethylated with age. CXCL9 is a small cytokine that has been shown to play an anti-fibrotic role in experimental chronic pancreatitis in rats and is a promising therapeutic target in pancreatic fibrosis [37]. S100a4 (encoding S100 calcium binding protein a4) has been shown to increase with age in a number of tissues [32]. However, it has not previously been established whether this is associated with changes in DNA methylation. Whether or not the age-related changes in DNA methylation observed at these loci are directly linked to the increased risk for type 2 diabetes will need to be established in future studies.
In conclusion, our study demonstrates that ageing leads to a relatively small number of transcriptional alterations in the endocrine pancreas, associated with an ‘inflammageing’ phenotype and type 2 diabetes signatures. The only other microarray analysis investigating the impact of ageing on the pancreatic islet transcriptome (interrogating ~13,000 mouse genes) [38] did not reported the same findings (there are several important differences between the two studies, including species, age time points, transcriptomic coverage and islet cell purity) and did not link the transcriptome to changes in epigenetic alterations. A very recent study of beta cell ageing in the mouse identified ~6,000 differentially expressed genes and over 14,000 differentially methylated regions, the majority of which were located more than 1 kb distal to transcriptional start sites. This study was conducted in sorted beta cells, therefore the impact of cellular processes described in our study (e.g. macrophage infiltration, collagen deposition) during ageing were missed [39]. We suggest that age-associated low-grade inflammation is linked with cellular (e.g. fibrosis) and metabolic dysfunction (e.g. de-regulation of genes involved in type 2 diabetes pathogenesis). These findings indicate that the local pancreatic environment (e.g. inflammation and fibrosis), in addition to systemic effects that occur with age, may be a major cause for the age-dependent decline of endocrine function. Furthermore, we propose that alterations in promoter DNA methylation can modulate these processes, although causal relationships need to be established.
Future studies aimed at assessing the biological roles of the genes highlighted in this study, using in vitro assays and/or in vivo animal models, have the potential to expand our knowledge on type 2 diabetes pathogenesis. It will be important to investigate whether the same mechanisms reported in this study are also observed in aged human islets.